Guided Therapeutics (GTHP) Cash & Equivalents Growth (1y) (2011 - 2026)
Guided Therapeutics (GTHP) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 72.43% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | -93.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -93.51% |
| Dec 31, 2025 | -83.76% |
| Sep 30, 2025 | -55.15% |
| Jun 30, 2025 | -32.73% |
| Mar 31, 2025 | -74.16% |
| Dec 31, 2024 | -34.35% |
| Sep 30, 2024 | -73.46% |
| Jun 30, 2024 | -79.75% |
| Mar 31, 2024 | -75.78% |
| Dec 31, 2023 | -74.45% |
| Sep 30, 2023 | -72.90% |
| Jun 30, 2023 | 204.48% |
| Mar 31, 2023 | 153.38% |
| Dec 31, 2022 | 259.72% |
| Sep 30, 2022 | 398.52% |
| Jun 30, 2022 | -51.63% |
| Mar 31, 2022 | -41.86% |
| Dec 31, 2021 | 253.30% |
| Sep 30, 2021 | -6.88% |
| Jun 30, 2021 | 20.84% |